Biotechnology company Qvin has secured approval from the Food and Drug Administration (FDA) in Thailand for its Q-Pad technology.
Q-Pad is claimed to be the first and only menstrual blood diagnostic device.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It has been designed to provide an accessible and non-invasive way to screen for High-Risk Human Papillomavirus (HR-HPV) and increase early detection between physician visits.
Qvin stated that Q-Pad is a new menstrual pad that can be used twice during menstruation to help remove the barriers of traditional pap smear testing, which can be hard to access, expensive and time-consuming.
The new diagnostic device was initially developed to identify biomarkers for HR-HPV. It has now been expanded to identify additional biomarkers and test for inflammation, blood sugar, fertility hormones, thyroid and ovarian reserve.
Q-Pad comprises a removable cotton strip that is sent to a lab for clinical testing. Users receive their laboratory results in the Qvin app.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataQvin CEO and co-founder Dr Sara Naseri said: “Receiving FDA approval in Thailand is exciting and contributes to our vision of a world where women do not die from cancers, like cervical cancer, that are entirely preventable if caught early.
“Approval not only marks a milestone on our journey to move the study of women forward, but it means we can provide accessible testing to millions of people in Thailand to identify HR-HPV earlier to try and eliminate cervical cancer there and look for more countries to follow.”
The company secured the approval in Thailand in partnership with N Health Laboratories and Bangkok Health Research Center (BHRC).
BHRC intends to conduct a 1,500-person comparative study using Q-Pads and PAP smears on HR-HPV.
The findings collected from the trial will be used to further understand the prevalence of HPV and cervical cancer in the country.
